Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis
30 nov. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment
18 oct. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
Patients In the Intermediate Size Patient Population Expanded Access (EA) Program Will Receive Intranasal Foralumab As Part of the At-Home Dosing InitiativeGreater Than 1 year Safety Exposure to...
Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab
16 oct. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
Numeric improvements were seen across key multiple sclerosis measures, including the Modified Fatigue Impact Scale, Expanded Disability Status Scale, Timed 25-Foot Walk test, Pyramidal Scores and...
Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)
13 oct. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
Five out of six patients in FDA authorized Expanded Access Program are showing a qualitative reduction in microglia activation (a key biomarker being observed)Foralumab to advance into Phase 2 human...
Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis
26 sept. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Study Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance
06 sept. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
The authors conclude that “nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer’s disease (AD)”FDA has cleared the IND for intranasal...
Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease
15 août 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
Foralumab to advance into Phase 2 human clinical trials using the world’s only fully human intranasal anti-CD3 monoclonal antibodyTrial to be overseen by Brigham and Women’s Hospital, a founding...
Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes
18 avr. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
CD3 antibody has emerged as an established and attractive target for Type 1 diabetes after the $2.9 billion acquisition of Provention Bio by SanofiMechanism of Action of Tiziana’s first-in-class, only...
Teneobio Announces FDA Clearance of IND for TNB-585 and Initiation of Phase I Clinical Studies for Metastatic Castrate Resistant Prostate Cancer
26 janv. 2021 08h00 HE
|
TeneoBio, Inc
NEWARK, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Teneobio, Inc. and its affiliate TeneoThree, Inc. announced today that their investigational new drug application (IND) for TNB-585, a bispecific...
Teneobio Reports Initial Data from a Phase I Study of TNB-383B in Relapsed Refractory Multiple Myeloma
07 déc. 2020 08h00 HE
|
TeneoBio, Inc
NEWARK, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage biotech company focused on discovery and development of novel multi-specific biotherapeutic antibodies, reported...